NCS Multistage Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NCS Multistage Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $142.47M | Mar 8, 2024 |
| FY2023 | Dec 31, 2022 | $155.63M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $118.50M | Mar 7, 2023 |
| FY2020 | Dec 31, 2020 | $27.38M | Mar 8, 2021 |
| FY2020 | Sep 30, 2020 | $16.31M | Mar 8, 2021 |
| FY2020 | Jun 30, 2020 | $8.73M | Mar 8, 2021 |
| FY2020 | Mar 31, 2020 | $54.55M | Mar 8, 2021 |
| FY2020 | Dec 31, 2019 | $52.09M | Mar 8, 2021 |
| FY2020 | Sep 30, 2019 | $60.77M | Mar 8, 2021 |
| FY2020 | Jun 30, 2019 | $39.77M | Mar 8, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $183.63M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $162.56M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $142.47M | Mar 10, 2025 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $50.18M | Mar 9, 2018 |
| FY2017 | Sep 30, 2017 | $55.96M | Mar 9, 2018 |
| FY2017 | Jun 30, 2017 | $36.86M | Mar 9, 2018 |
| FY2017 | Mar 31, 2017 | $58.64M | Mar 9, 2018 |
| FY2017 | Dec 31, 2016 | $35.44M | Mar 9, 2018 |
| FY2017 | Sep 30, 2016 | $28.65M | Mar 9, 2018 |
| FY2017 | Jun 30, 2016 | $11.28M | Mar 9, 2018 |
| FY2017 | Mar 31, 2016 | $23.11M | Mar 9, 2018 |
| FY2017 | Dec 31, 2015 | $114.01M | Mar 9, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $11.12M | Mar 8, 2021 |
| FY2020 | Sep 30, 2020 | $5.60M | Mar 8, 2021 |
| FY2020 | Jun 30, 2020 | $1.70M | Mar 8, 2021 |
| FY2020 | Mar 31, 2020 | $22.94M | Mar 8, 2021 |
| FY2020 | Dec 31, 2019 | $25.11M | Mar 8, 2021 |
| FY2020 | Sep 30, 2019 | $27.56M | Mar 8, 2021 |
| FY2020 | Jun 30, 2019 | $15.67M | Mar 8, 2021 |
| FY2020 | Mar 31, 2019 | $25.14M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $23.34M | Mar 3, 2020 |
| FY2019 | Sep 30, 2018 | $33.11M | Mar 3, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.75M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $6.59M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($3.15M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($1.10M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($4.73M) | Mar 7, 2023 |
| FY2020 | Dec 31, 2020 | $8.57M | Mar 8, 2021 |
| FY2020 | Sep 30, 2020 | ($5.86M) | Mar 8, 2021 |
| FY2020 | Jun 30, 2020 | ($8.76M) | Mar 8, 2021 |
| FY2020 | Mar 31, 2020 | ($51.55M) | Mar 8, 2021 |
| FY2020 | Dec 31, 2019 | ($2.18M) | Mar 8, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.54M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $4.33M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($5.53M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($2.25M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($5.12M) | Mar 7, 2023 |
| FY2020 | Dec 31, 2020 | ($57.0K) | Mar 8, 2021 |
| FY2020 | Sep 30, 2020 | ($7.47M) | Mar 8, 2021 |
| FY2020 | Jun 30, 2020 | ($14.23M) | Mar 8, 2021 |
| FY2020 | Mar 31, 2020 | ($49.68M) | Mar 8, 2021 |
| FY2020 | Dec 31, 2019 | $1.32M | Mar 8, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.00M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $2.00M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $2.50M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $2.70M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $2.10M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $1.90M | Mar 8, 2022 |
| FY2021 | Dec 31, 2019 | $2.80M | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | $3.80M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $3.00M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $3.30M | Mar 8, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.85M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $57.82M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $56.52M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $58.34M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $49.09M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $59.43M | Mar 8, 2022 |
| FY2021 | Dec 31, 2019 | $88.55M | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | $82.81M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $64.71M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $37.06M | Mar 8, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.18M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $12.73M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $4.77M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($1.42M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $11.58M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $35.12M | Mar 8, 2022 |
| FY2021 | Dec 31, 2019 | $17.95M | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | $14.03M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $16.11M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $10.68M | Mar 8, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.20M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $1.31M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $1.88M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $1.04M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $495.0K | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $2.10M | Mar 8, 2022 |
| FY2021 | Dec 31, 2019 | $6.12M | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | $11.13M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $5.37M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $1.16M | Mar 8, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $181.20M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $152.81M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $152.03M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $138.60M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $142.33M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $138.68M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $202.58M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $229.70M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $463.91M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $326.83M | Mar 9, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.10M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $36.70M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $42.64M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $29.34M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $31.66M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $25.19M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $39.03M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $53.47M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $94.92M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $149.35M | Mar 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $126.24M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $98.84M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $91.62M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $91.03M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $92.58M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $93.61M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $144.61M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $161.30M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $356.85M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $177.48M | Mar 9, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.39M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $15.22M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $15.22M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $15.22M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $15.22M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $15.22M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $15.22M | Mar 8, 2021 |
| FY2020 | Dec 31, 2018 | $23.11M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $184.48M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $122.08M | Mar 8, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($235.28M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($259.02M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($265.62M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($262.46M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($261.36M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | ($256.63M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($199.03M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($166.21M) | Mar 3, 2020 |
| FY2018 | Jan 1, 2018 | $24.11M | Mar 8, 2019 |
| FY2018 | Dec 31, 2017 | $23.86M | Mar 8, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.73M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $25.88M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $16.72M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $16.23M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $22.17M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $15.55M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $11.24M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $25.13M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $33.81M | Mar 8, 2019 |
| FY2018 | Dec 31, 2016 | $18.28M | Mar 8, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $22.41M | Mar 8, 2019 |
| FY2017 | Dec 31, 2017 | $24.61M | Mar 9, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 7, 2023 |
| FY2020 | Dec 31, 2020 | 3 | Mar 8, 2021 |
| FY2020 | Sep 30, 2020 | (2) | Mar 8, 2021 |
| FY2020 | Jun 30, 2020 | (3) | Mar 8, 2021 |
| FY2020 | Mar 31, 2020 | (21) | Mar 8, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 8, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 7, 2023 |
| FY2020 | Dec 31, 2020 | 3 | Mar 8, 2021 |
| FY2020 | Sep 30, 2020 | (2) | Mar 8, 2021 |
| FY2020 | Jun 30, 2020 | (3) | Mar 8, 2021 |
| FY2020 | Mar 31, 2020 | (21) | Mar 8, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 8, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.55M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 2.51M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 2.44M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | 2.41M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 2.38M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | 2.36M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | 2.34M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | 45.07M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | 43.91M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | 34.01M | Mar 9, 2018 |